All About Multiple Sclerosis

More MS news articles for September 2003

Effector stage CC chemokine receptor-1 selective antagonism reduces multiple sclerosis-like rat disease

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14512166&dopt=Abstract

J Neuroimmunol. 2003 Sep;142(1-2):75-85
Eltayeb S, Sunnemark D, Berg AL, Nordvall G, Malmberg A, Lassmann H, Wallstrom E, Olsson T, Ericsson-Dahlstrand A.
Neuroimmunology Unit, Department of Medicine, Karolinska Institutet, SE-171 76, Stockholm, Sweden

We have studied the role of the chemokine receptor CCR1 during the effector stage of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in DA rats.

In situ hybridization histochemistry revealed local production of the CCR1 ligands CCL3 (MIP-1alpha) and CCL5 (RANTES), as well as large numbers of CCR1 and CCR5 expressing cells within inflammatory brain lesions.

A low-molecular weight CCR1 selective antagonist potently abrogated both clinical and histopathological disease signs during a 5-day treatment period, without signs of peripheral immune compromise.

Thus, we demonstrate therapeutic targeting of CCR1-dependent leukocyte recruitment to the central nervous system in a multiple sclerosis (MS)-like rat model.